Skip to content
Screener

Abbott ABT Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)

Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) at other companies

Haemonetics logo
HaemoneticsHAE
$40.69M-10.1%
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$12.6B+13.0%
Gross profit$7.3B+15.6%
Operating income$1.7B-17.5%
Net income$928.0M-47.8%
EPS (diluted)$0.53-47.5%

Balance sheet

See full
Cash & equivalents$5.1B-26.6%
Total debt$32.6B+143%
Total equity$51.1B+1.1%
Total assets$109.22B+30.0%

Cash flow

See full
Operating cash flow$2.5B+21.5%
CapEx$497.0M-1.0%
Free cash flow$2.0B+28.9%

Valuation

See full
Market cap$186.55B-18.4%
Enterprise value$214.06B-9.0%
P/E34.4×+18.0×
P/S-1.3×

Profitability

See full
Gross margin56.6%+0.6pp
Operating margin15.8%-1.7pp
Net margin11.6%-20.8pp
FCF margin16.8%+1.1pp

Returns & leverage

See full
Return on equity10.7%-20.4pp
Debt / equity0.6×+0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.

The source filing: Abbott’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050134

The gross amount of amortizable intangible assets, primarily product rights and technology, was $39.8 billion as of June 30, 2026, and $27.6 billion as of December 31, 2025. The gross amount of amortizable intangible assets increased by $12.3 billion in the first six months of 2026 due to the completion of the Exact Sciences acquisition. Accumulated amortization was $24.3 billion and $23.3 billion as of June 30, 2026, and December 31, 2025, respectively. Abbott’s estimated annual amortization expense for intangible assets is approximately $2.6 billion in 2026, $2.3 billion in 2027, $1.8 billion in 2028, $1.7 billion in 2029, and $1.5 billion in 2030.

Item 1. Financial Statements and Supplementary Data

FAQ

What is Abbott's finite-lived intangible assets - expected amortization expense (year one)?
Abbott (ABT) reported finite-lived intangible assets - expected amortization expense (year one) of $1.5B in Q2 2026.
How has Abbott's finite-lived intangible assets - expected amortization expense (year one) changed year-over-year?
Abbott's finite-lived intangible assets - expected amortization expense (year one) increased by 150.0% year-over-year, from $600M to $1.5B.
What is the long-term trend for Abbott's finite-lived intangible assets - expected amortization expense (year one)?
Over 3 years (2022 to 2025), Abbott's finite-lived intangible assets - expected amortization expense (year one) has grown at a -32.9% compound annual growth rate (CAGR), from $1.2B to $363M.
What does finite-lived intangible assets - expected amortization expense (year one) mean?
This metric forecasts the amortization expense expected to be recognized in the upcoming fiscal year for intangible assets with finite useful lives. It provides visibility into the non-cash earnings impact of previously acquired intangible assets. Analysts use this to refine future earnings projections and cash flow models.

Ask your AI about Abbott's finite-lived intangible assets - expected amortization expense (year one).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude